Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose TBI-based allogeneic hematopoietic cell transplantation vs conventional chemotherapy as consolidation for older AML in first remission
2007-003514-34Phase 3Completed
- Sponsor
- EBMT
- Start
- Sep 2008
- Modality
- Small Molecules, Peptides, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of mitoxantrone, cytarabine, fludarabine, cyclosporine and mycophenolate mofetil in acute myeloid leukemia (AML) and myelodysplastic syndrome with excess blasts (MDS-EB) (2 arms), sponsored by EBMT. Primary endpoint: Leukemia-free survival. Started Sep 2008; status: completed.
02
Drugs
mitoxantronecytarabinefludarabinecyclosporinemycophenolate mofetil
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome with excess blasts (MDS-EB)
Beyond the preview
Go deeper on 2007-003514-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003514-34.